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ABSTRACT 
Cancer has become a solemn threat to the life of human beings universally. Various strategies are available to steadfastness cancer; however they 
are not so effective owed to their serious side effects, noxious effect to healthy cells and non- specificity to cancer cells targeting. To tenacity 
above facts we try to deed inherent characters of cancer cells. HA was used as a targeting agent for drug delivery to breast cancer cells. In this 
work nanoparticles were equipped using chitosan and sodium tripolyphosphate encapsulating methotrexate. Methotrexate (Mtx) a folic acid 
antagonist that inhibits dihydrofolatereductase (DHFR) and blocks conversion of dihydrofolic acid (DHFA) to tetrahydrofolic acid (THFA) of the 
cell cycle. Chitosan anchored nanoparticles were prepared by ionotropic gelation method by means of sodium tripolyphosphate and evalauted 
for in-vitro drug release study with dialysis membrane. Result depicts that drug releases from chitosan nanoparticles in sustained manner over a 
prolonged episode of time from the NPs as the medium acidity enhanced at the target site, not in plasma. In conclusion, chitosan anchored 
nanoparticles of MTX could be well thought-out as probable candidate for drug delivery in the treatment of breast cancer. 
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INTRODUCTION 
Cancer is merely the gain of oncogenes and the loss of 
tumour suppressor genes. Genetic abnormalities found in 
cancer classically affect two general classes of genes. Cancer-
promoting oncogenes are naturally activated in cancer cells, 
giving those cells new properties, such as hyperactive 
growth and division, protection against programmed cell 
death, loss of respect for normal tissue boundaries, and the 
capability to become established in varied tissue 
environments. One in eight women in the United States will 
be diagnosed with breast cancer in her lifetime.1 Breast 
cancer is the most frequently diagnosed cancer in women. It 
is the second leading cause of cancer death among women. 
Each year it is estimated that over 252,710 women in our 
country will be diagnosed with breast cancer and more than 
40,500 will die. Although breast cancer in men is rare, an 
estimated 2,470 men will be diagnosed with breast cancer 
and approximately 460 will die each year. On average, every 
2 minutes a woman is diagnosed with breast cancer and 1 
woman will die of breast cancer every 13 minutes. In current 
years, perhaps coinciding with the failure in prescriptive 
hormone replacement therapy after menopause, we have 
seen a gradual reduction in female breast cancer incidence 
rates among women aged 50 and older.2  
Delivery of drugs through nanoparticulate grounded drug 
carriers has reached an attractive courtesy, mainly in the 
treatment of different types of malignancies. These sub- 
micron sized particles have a potential to target the tumour 
sites passively, through enhanced permeation and retention 
effect. Nanoparticles are multipurpose nanosized structures 
which have found many claims in medical practice. 
Functionality of nanoparticles can be derived from their 
inherent properties as a result of their sizes. For example, 
nanoparticles of within a specific size range can easily evade 
the reticulo endothelial system (RES) and increase the 
biological half life of their drug payload. Nanoparticles also 
offers advantage of targeted or site specific drug delivery to 
of chemotherapeutics and other drugs to affected cells over 
extended period of time thereby reducing toxic side effects. 
Advances in the technology assists drug to be delivered 
passively to the target site, preserving their efficacy and 
creating a host of prospects for cancer chemotherapy 3-10 
Polymeric NPs are considered as optimal carriers for drug 
delivery due to their appropriate characteristics. One of the 
most polymers used in the field of nano-drug delivery 
systems is Chitosan. 
Many applications and attentions to this polymer in drug 
delivery field is because of its properties such as 
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formulations and techniques of the production conformed by 
various types of drugs (e.g. hydrophilic or hydrophobic 
molecules or macromolecules), biodegradability and 
biocompatibility, FDA approval in drug delivery systems for 
medical applications, protection of drug from degradation, 
possibility of sustained release, facility in modifying surface 
properties, resulting in better interaction with biological 
materials and facility in targeting NPs to specific points 11. 
Therefore, chitosan NPs have potential to improve drug 
delivery systems and overcome many problems related to 
the treatment of breast tumors. 
MTX, a folic acid antagonist, generally used as clinical 
chemotherapy agent and highly efficacious antineoplastic 
drug 12-13. MTX inhibits Dihydrofolate Reductase (DHFR) and 
interfere with tumor cell DNA, RNA and consequently 
protein synthesis, leads to inhibition of the proliferation of 
tumor cells 14. However, using methotrexate has been 
restricted because of limitations such as low half-life in 
plasma, low penetration into the brain and dose-dependent 
systemic side effects. To overcome this problem, MTX can be 
loaded in various NPs were prepared by various authors. 15-
18 
MATERIALS AND METHODS 
Materials:  
Methotrexate was received as gift sample from Khandelwal 
Laboratories Pvt. Ltd. Pune, India. Chitosan was obtained 
from Central Institute of Fisheries, Cochin; TPP was 
purchased from Advance scientific Labs. Bhopal. All the 
chemicals and solvents were analytical grade. 
Method 
Preparation of chitosan nanoparticles  
Chitosan Nanoparticles were prepared by using ionotropic 
gelation technique. A requisite quantity of chitosan was 
dissolved in 0.1 % glacial acetic acid and water in the ratio of 
9:1 under magnetic stirring at 3000 rpm for 4 hrs at room 
temperature for complete dissolution. Chitosan (Cs)solution 
was adjusted to pH 6.2 was performed by addition of 
appropriate volumes of 0.1 N NaOH, such pH value maintains 
chitosan in its soluble form at all examined concentration 
(Jain et al. 2008). Then solution of TPP was prepared at 
different concentrations in 0.1 N sodium hydroxide and this 
solution was added drop by drop in the above prepared 
chitosan solution with continuous stirring for 30 hr. Then 
required quantity of methotrexate (Mtx) was dissolved in 0.1 
N sodium hydroxide to make 1% solution and gradually 
added in above chitosan solution drop wise. The mixture was 
stirred at room temperature for 30 min to obtain Nps.  Also, 
spontaneously formed NPs were separated by centrifugation 
at 10000 rpm for 10 min and supernatant discarded and 
sediment was poured in dialysis bag to dialyzed three times 
with phosphate buffer to remove free drug from the 
formulation which was then determined 
spectrophotometrically at 307 nm by UV spectrophotometer 
Shimadzu 1800 to determine directly the amount of drug 
loaded in the system. The dialyzed formulation was 
lyophilized for further characterization. 
Preparation of hyaluronic acid (HA) anchored chitosan 
nanoparticles 
Finely requisite quantity of HA (10 mg) was dissolved in 10 
ml PBS (pH 6.0) with continuous stirring and the reaction 
was performed at room temperature using EDC (1- ethyl-3-
(3-dimethylanminopropyl) carbodiimide hydrochloride for 
1.5hrs under magnetic stirring at 3000 rpm. This solution 
was added drop wise in above solution with continuous 
stirring. 
Nanoparticles were formed on solvent interface. Then 
solvent was evaporated at room temperature. The resulting 
suspension of nanoparticles was filtered through 0.45 µm 
membrane filter (Millipore) and centrifuged for 45 min at 
10,000 rpm (Remi, Mumbai, India). The supernatant was 
discarded and pellet containing hyaluronic acid (HA) 
anchored chitosan nanoparticles were lyophilized and kept 
preserved. The amount of HA on the surface of nanoparticles 
was assessed by change in zeta potential. The two process 
variables (incubation time and total nanoparticulate 
formulation to HA weight ratio) were optimized by 
measuring change in zeta potential (the surface charge 
density) 
Characterization  
In-vitro drug release study  
In-vitro drug release profile was performed by using dialysis 
bag method with the help of dialysis membrane (Himedia, 
Mumbai India) molecular weight cut off 12000-14000 Da. 
The release rate of drug from formulation depends on 
various factors like polymer ratio, polymer degradation or 
erosion, solubility. In the present study nanoparticles 
dispersion was filled in the dialysis tube and immersed in 
Phosphate saline buffer (pH 7.4) under continuous magnetic 
stirring and the temperature should be maintained at 
37±1ºC throughout the procedure. At specific time intervals, 
the samples were taken and diluted to determine the 
concentration UV spectrophotometer (Shimadzu 1800) at 
307 nm and shown in the table 1 and figure 2. 
Table 1: In-vitro cumulative percent drug release from 
formulations in phosphate buffer (pH 7.4) 
Time 
(in hrs) 
Cumulative % Drug release from 
hyaluronic acid anchored chitosan  
0.25 0.89 ± 0.32 
0.50 1.88 ± 0.42 
1 6.14 ± 0.38 
2 18.24 ± 0.28 
4 30.85 ± 0.42 
8 43.42 ± 3.25 
12 50.42 ± 2.14 
24 54.13 ± 3.42 
48 59.42 ± 2.17 
72 63.85 ± 1.62 
84 68.74 ± 1.90 
96 72.87 ± 2.54 
(n=3) Mean ± S.D. 
 
Figure 2: In-vitro Cumulative % Drug release from 
hyaluronic acid anchored chitosan nanoparticles and 
blank chitosan nanoparticles 
0 
20 
40 
60 
80 
100 
120 
0.25 0.5 1 2 4 8 12 24 48 72 84 96 
%
 D
ru
g 
R
e
le
as
e
 
Time in hrs 
CSNPs HACSNPs 
Thagele et al                                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(1):6-8 
ISSN: 2250-1177                                                                                  [8]                                                                                 CODEN (USA): JDDTAO 
RESULTS  
In-vitro drug release study was performed using dialysis bag 
method with the help of dialysis membrane. The release 
studies were carried out by plotting the graph.  In-vitro drug 
release studies Drug release pattern of blank chitosan 
nanoparticles and hyaluronic acid anchored chitosan 
nanoparticles was studied at pH 7.4, and it is confirmed from 
Fig. 4.2 that the release of drug from polymeric nanoparticles 
was sustained as compared to blank chitosan nanoparticles. 
Interestingly, more drug release was observed at cancer cell 
pH of 5.6 and least at plasma pH of 7.4 from the hyaluronic 
acid anchored chitosan nanoparticles. However, there was 
no such distinction of release pattern in blank formulation 
was obtained. This finding is unique and of significance, that 
the drug will be released at the target site, not in plasma.   
CONCLUSION 
This study reports the preparation of hyaluronic acid 
anchored chitosan nanoparticles via ionotropic gelation 
method for the delivery of the anticancer drug to breast 
cancer cells. The prepared nanoparticles were in nm range 
and In-vitro release profile show sustained behavior due to 
slow diffusion of drug from polymeric matrix follow non- 
fickian diffusion mechanism. The results indicated that 
hyaluronic acid anchored chitosan nanoparticles could be 
effective in controlled release of drug for prolonged period of 
time. Therefore, it is concluded that it could be considered 
hopeful carrier for targeted drug delivery to breast cancer 
cells.  
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